HK1202243A1 - Methods for improving cognitive function and decreasing heart rate - Google Patents

Methods for improving cognitive function and decreasing heart rate Download PDF

Info

Publication number
HK1202243A1
HK1202243A1 HK15102730.4A HK15102730A HK1202243A1 HK 1202243 A1 HK1202243 A1 HK 1202243A1 HK 15102730 A HK15102730 A HK 15102730A HK 1202243 A1 HK1202243 A1 HK 1202243A1
Authority
HK
Hong Kong
Prior art keywords
dha
acid
dosage form
subject
memory
Prior art date
Application number
HK15102730.4A
Other languages
English (en)
Chinese (zh)
Inventor
‧尤科-毛羅
K‧尤科-毛罗
Original Assignee
帝斯曼知识产权资产有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 帝斯曼知识产权资产有限公司 filed Critical 帝斯曼知识产权资产有限公司
Publication of HK1202243A1 publication Critical patent/HK1202243A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
HK15102730.4A 2009-02-02 2015-03-17 Methods for improving cognitive function and decreasing heart rate HK1202243A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14931009P 2009-02-02 2009-02-02
US61/149,310 2009-02-02
US18354809P 2009-06-02 2009-06-02
US61/183,548 2009-06-02

Publications (1)

Publication Number Publication Date
HK1202243A1 true HK1202243A1 (en) 2015-09-25

Family

ID=42041547

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102730.4A HK1202243A1 (en) 2009-02-02 2015-03-17 Methods for improving cognitive function and decreasing heart rate

Country Status (8)

Country Link
US (2) US20100203123A1 (enExample)
EP (2) EP2939671A1 (enExample)
JP (5) JP2012516852A (enExample)
CN (3) CN104042600A (enExample)
AU (2) AU2016201382A1 (enExample)
CA (1) CA2751275A1 (enExample)
HK (1) HK1202243A1 (enExample)
WO (1) WO2010088700A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
CA2833219A1 (en) 2011-05-19 2012-11-22 The Regents Of The University Of California Nutraceutical composition comprising fisetin and docosahexaenotic acid useful in the treatment of cognitive decline
US20130084272A1 (en) * 2011-09-29 2013-04-04 Philippe Perrin Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
HK1213740A1 (zh) * 2013-03-15 2016-07-15 Inspyr Therapeutics, Inc. 制备抗癌症组合物的方法
EP4223861A3 (en) 2013-12-20 2023-11-01 Mara Renewables Corporation Methods of recovering oil from microorganisms
TR201503136A2 (tr) * 2015-03-16 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve esansiyel yağ asitlerinin farmasötik kompozisyonları.
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
WO2018116093A1 (en) 2016-12-22 2018-06-28 MARA Renewables Corporation Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism
JP7101087B2 (ja) * 2018-09-05 2022-07-14 株式会社 伊藤園 軽度認知障害に対する緑茶成分の有効性評価方法
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
AU2020325063A1 (en) * 2019-08-08 2022-03-24 Swinburne University Of Technology Uses of long-chain polyunsaturated fatty acids
BR112022019834A2 (pt) 2020-04-03 2022-12-06 Mara Renewables Corp Óleo microbiano, e, método de compor uma biomassa
DE102020115238A1 (de) * 2020-06-09 2021-12-09 Pm-International Ag Nahrungsergänzungsmittel und Nahrungsmittel
CN115867980A (zh) * 2020-07-02 2023-03-28 派尔疗法美国股份有限公司 用于生成和施用数字治疗安慰剂和伪物的系统、方法和设备
WO2022152912A1 (en) * 2021-01-15 2022-07-21 Cambridge Cognition Limited Methods and systems of identifying individuals for perioperative neurocognitive disorder and/or post-viral cognitive impairment
EP4637824A1 (en) * 2023-01-18 2025-10-29 Bioventures, Llc Method of preventing and treating alzheimer's disease and related dementias with drugs inhibiting the interaction between 14-3-3g protein and hexokinase-1 protein
JP2025079778A (ja) * 2023-11-10 2025-05-22 ダイドーグループホールディングス株式会社 生理機能改善用の組成物
WO2025100476A1 (ja) * 2023-11-10 2025-05-15 国立大学法人京都大学 生理機能改善用の組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
EP0707487B1 (en) * 1993-06-09 2004-04-14 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders
WO1996005278A1 (de) 1994-08-16 1996-02-22 Dr. Frische Gmbh Verfahren zur gewinnung von nicht wasserlöslichen, nativen produkten aus nativen stoffgemengen mit hilfe der zentrifugalkraft
AU5346296A (en) * 1995-04-17 1996-11-07 Japan As Represented By Director-General Of Agency Of Industrial Science And Technology Novel microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fa tty acids by using the microorganisms
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
WO2000050547A1 (en) 1999-02-26 2000-08-31 Monsanto Company Process for separating a triglyceride comprising a docosahexaenoic acid residue from a mixture of triglycerides
AU2001232786A1 (en) 2000-01-11 2001-07-24 Monsanto Company Process for making an enriched mixture of polyunsaturated fatty acid esters
KR20100051131A (ko) 2000-01-19 2010-05-14 마텍 바이오싸이언스스 코포레이션 무용매 추출 방법
WO2001076715A2 (en) 2000-04-12 2001-10-18 Westfalia Separator Industry Gmbh Method for the fractionation of oil and polar lipid-containing native raw materials
EP1392623A4 (en) 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS
EP2275101A1 (en) 2001-05-14 2011-01-19 Martek Biosciences Corporation Polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes, and its uses
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
EP2266525B1 (en) 2002-05-03 2012-07-11 Martek Biosciences Corporation High quality lipids and methods for producing by enzymatic liberation from biomass
CA2594781A1 (en) * 2005-01-24 2006-07-27 Pronova Biocare As Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
NZ563659A (en) * 2005-05-23 2011-05-27 Massachusetts Inst Technology Use of compositions containing omega 3 or 6 fatty acids and either uridine or choline for treating Alzheimer's and other memory disorders
MX336435B (es) * 2005-07-08 2016-01-19 Dsm Ip Assets Bv Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.
WO2009002145A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
CA2692355C (en) 2007-06-29 2018-09-11 Martek Biosciences Corporation Production and purification of esters of polyunsaturated fatty acids
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid

Also Published As

Publication number Publication date
EP2391361A1 (en) 2011-12-07
JP2018104477A (ja) 2018-07-05
US20130172412A1 (en) 2013-07-04
AU2016201382A1 (en) 2016-03-24
JP2020050675A (ja) 2020-04-02
WO2010088700A1 (en) 2010-08-05
CN108324706A (zh) 2018-07-27
AU2017245327A1 (en) 2017-11-02
JP2012516852A (ja) 2012-07-26
US20100203123A1 (en) 2010-08-12
CA2751275A1 (en) 2010-08-05
JP2022059063A (ja) 2022-04-12
EP2939671A1 (en) 2015-11-04
CN102365087A (zh) 2012-02-29
CN104042600A (zh) 2014-09-17
JP2015143248A (ja) 2015-08-06
AU2010207929A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
HK1202243A1 (en) Methods for improving cognitive function and decreasing heart rate
Wood et al. Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer’s disease
JP6419927B2 (ja) 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
US11413263B2 (en) Reducing the risk of pathological effects of traumatic brain injury
ES2661217T3 (es) Composiciones y métodos para reducir los triglicéridos sin aumentar los niveles de LDL-C en un sujeto en terapia simultánea con estatinas
ES2750365T3 (es) Composición para el tratamiento y/o la prevención de enfermedades cardiovasculares
US20140357717A1 (en) Methods of treating hypertriglyceridemia
US20110086914A1 (en) Methods for Treating Traumatic Brain Injury
US20110177061A1 (en) Methods of treating and preventing neurological disorders using docosahexaenoic acid
AU2010207929B2 (en) Methods for improving cognitive function and decreasing heart rate
HK1172241B (en) Reducing the risk of pathological effects of traumatic brain injury
HK1172241A (en) Reducing the risk of pathological effects of traumatic brain injury